恒瑞医药HRS-8364片临床试验获批

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of its innovative anti-tumor drug HRS-8364, which is intended for the treatment of advanced solid tumors, with no similar drugs approved in the domestic and international markets [1] Company Summary - Heng Rui Medicine announced the receipt of the clinical trial approval notice for HRS-8364 tablets [1] - HRS-8364 is an innovative anti-tumor drug independently developed by Heng Rui Medicine [1] - The drug is aimed at treating advanced solid tumors [1] Industry Summary - There are currently no similar drugs approved for market use, either domestically or internationally, for the treatment of advanced solid tumors [1]